Tag Archives: Boston Cell Standards

October 2023—Visiopharm and Boston Cell Standards announced they are partnering to integrate immunohistochemistry calibration standards with image analysis software for quality assurance. The joint technology solution will enable laboratories to meet key provisions of regulatory changes proposed in an editorial published in Archives of Pathology & Laboratory Medicine.

Oct. 6, 2022—Boston Cell Standards today announced it received 510(k) clearance from the FDA for its IHControls breast cancer panel, positive controls to monitor the performance of the immunohistochemical staining process for HER2, ER, and PR IHC assays.